Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

7.1K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
7.1K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

12.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
12.8K
Lineage Commitment01:21

Lineage Commitment

3.6K
Commitment is the  process whereby stem cells:
3.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

7.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.2K
Tumor Progression02:07

Tumor Progression

6.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.1K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis.

Cancer research communications·2026
Same author

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Blood advances·2026
Same author

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Blood advances·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.

Blood·2026

Related Experiment Video

Updated: Nov 3, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.8K

Exploring the pathways to chronic lymphocytic leukemia.

Freda K Stevenson1, Francesco Forconi1,2, Thomas J Kipps3

  • 1School of Cancer Sciences, Cancer Research UK Southampton Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Blood
|June 2, 2021
PubMed
Summary

Chronic lymphocytic leukemia (CLL) is now classified into mutated and unmutated types based on IGHV gene mutation status. This classification impacts treatment strategies and understanding of disease biology, though challenges remain.

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.8K

Related Experiment Videos

Last Updated: Nov 3, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.9K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.8K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of malignant lymphocytes.
  • Advances in understanding CLL cell biology have improved patient assessment and treatment, particularly targeting surface immunoglobulin receptor signaling and survival pathways.
  • CLL classification based on IGHV mutational status (mutated [M-CLL] vs. unmutated [U-CLL]) reveals distinct biological and clinical behaviors.

Purpose of the Study:

  • To elucidate the distinct biological origins and clinical behaviors of mutated and unmutated CLL.
  • To highlight the role of microenvironmental interactions and T-cell help in modulating CLL cell fate.
  • To identify remaining challenges in CLL management, including therapeutic resistance and Richter transformation.

Main Methods:

  • Classification of CLL based on IGHV sequence mutational status.
  • Analysis of cellular origin, biology, epigenetics, genetics, and clinical behavior for M-CLL and U-CLL subtypes.
  • Investigation of microenvironmental interactions and T-cell help in disease progression.

Main Results:

  • U-CLL originates from the natural antibody repertoire, potentially driven by superantigens like IGHV1-69.
  • Both M-CLL and U-CLL cells undergo cycles of proliferation and apoptosis evasion, influenced by self-antigen stimulation.
  • M-CLL exhibits a greater tendency towards anergy compared to U-CLL, with T-cell help significantly impacting cell fate and clinical outcomes.

Conclusions:

  • IGHV mutational status is a critical determinant of CLL biology and clinical behavior, necessitating distinct therapeutic approaches.
  • Microenvironmental factors, especially T-cell interactions, play a crucial role in modulating CLL progression and response to therapy.
  • Continued research into CLL biology is essential to overcome challenges such as therapeutic escape, Richter transformation, and immunosuppression.